Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Research Reveals Disconnect Between Parents and Physicians in Pediatric Clinical Trial Recruitment

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Study from Blue Chip Patient Recruitment provides best practices for recruiting pediatric patients in clinical trials.

Blue Chip Patient Recruitment, a global, full-service strategic marketing practice of Blue Chip Marketing Worldwide that specializes in accelerating enrollment of clinical trials, has announced results of its latest research study on how physicians and clinical trial coordinators can successfully accelerate enrollment of pediatric clinical trials.

The white paper, titled “Accelerating Recruitment for Pediatric Clinical Trials: Connecting Parents, Children and Investigators” and available at www.bcpatientrecruitment.com/whitepaper, summarizes the results of primary market research that explores the motivations and barriers a parent faces when considering clinical trial opportunities for their child and the challenges physicians experience when recruiting children for clinical trials.

“Understanding the true motivations and worries behind a parent’s decision to enroll their child in a clinical trial is essential for successful enrollment,” says Neil Weisman, EVP/general manager of Blue Chip Patient Recruitment. “With adult conditions starting to emerge in children more frequently and since many medications have never been studied in children, sponsors and investigators will need this type of research to successfully address changing pediatric healthcare needs.”

Key findings include:

The study shows that even though parents may be very or somewhat satisfied with their child’s current medication, physicians should always educate and inform parents of potential clinical trial opportunities. Nearly 85% of the parents who were “very or somewhat satisfied” with their child’s current medication indicated they would be willing to switching their child to a new medication option.

To better connect with parents, physicians should focus on how the trial can potentially benefit their child as opposed to more altruistic-based communications. More than 53% of parents cited “my child might benefit” as their top motivation for enrolling their child in a clinical trial while 74% of physicians chose “benefit other children in the future” as their main point when educating parents on clinical trial opportunities.

Physicians need to understand and create communications based on how their patients’ parents prefer to receive information about potential pediatric clinical trial opportunities. Listed as the most preferred method of communications, 46% of parents indicated they prefer to receive information about pediatric clinical trial opportunities from their physicians by email, whereas only 6% of physicians stated that email was the most effective way to communicate with parents. And while not one doctor stated a physical letter was effective, nearly 30% of parents preferred to receive clinical trial information via a physical letter.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!